Vaccines — Global Clinical Trial Landscape

The global vaccine clinical trials landscape has undergone a profound transformation since the COVID-19 pandemic, shifting from a traditionally conservative field to a dynamic, innovation-driven sector. This evolution reflects both technological advances and changing global research dynamics. The geographic distribution of vaccine trials has realigned, with the Asia-Pacific region emerging as a dominant force due to its growing research capacity, supportive regulatory environments, and cost efficiencies.

Meanwhile, North America continues to lead through sustained investment in research and development, robust clinical research organization (CRO) networks, and advanced trial infrastructure. In contrast, Europe’s share of vaccine trials has declined, challenged by complex multi-country approval processes and slower regulatory harmonization.

Collectively, these shifts signal a new phase of globalization in vaccine development — one defined by regional specialization, accelerated innovation, and evolving competitive advantages across the global clinical research ecosystem.